Literature DB >> 16483911

Acetaminophen or NSAIDs for the treatment of osteoarthritis.

Bernard Bannwarth1.   

Abstract

Although non-pharmacological interventions are the cornerstone of osteoarthritis management, analgesics are an important component of treatment during the symptomatic periods of the disease. In this respect, current practice guidelines advocate the use of a simple analgesic, acetaminophen, or a non-steroidal anti-inflammatory drug (NSAID), given either systemically or topically as first-line or second-line drug therapies. The present paper aims first to assess the evidence for the efficacy and safety of these medications. Given the increasing importance of patient involvement in decision-making, the following key practical issue regarding acetaminophen and NSAIDs will then be addressed: 'which drug do patients prefer?' Regarding NSAIDs, a further question concerns the place for non-selective agents and cyclo-oxygenase-2 (COX-2) selective inhibitors (coxibs) in the light of new warnings and contraindications concerning coxibs in patients with increased risk of cardiovascular thrombotic events.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16483911     DOI: 10.1016/j.berh.2005.09.004

Source DB:  PubMed          Journal:  Best Pract Res Clin Rheumatol        ISSN: 1521-6942            Impact factor:   4.098


  9 in total

1.  Current evidence for osteoarthritis treatments.

Authors:  Ananthila Anandacoomarasamy; Lyn March
Journal:  Ther Adv Musculoskelet Dis       Date:  2010-02       Impact factor: 5.346

2.  Acupuncture for Improving Chronic Back Pain, Osteoarthritis and Headache.

Authors:  Karen J Sherman; Remy R Coeytaux
Journal:  J Clin Outcomes Manag       Date:  2009-05-01

3.  Incorporation of aggrecan in interpenetrating network hydrogels to improve cellular performance for cartilage tissue engineering.

Authors:  Ganesh C Ingavle; Anthony W Frei; Stevin H Gehrke; Michael S Detamore
Journal:  Tissue Eng Part A       Date:  2013-03-26       Impact factor: 3.845

4.  Comparative assessment of the effectiveness and tolerability of lornoxicam 8 mg BID and diclofenac 50 mg TID in adult indian patients with osteoarthritis of the hip or knee: A 4-week, double-blind, randomized, comparative, multicenter study.

Authors:  Arvind Goregaonkar; K J Mathiazhagan; Ravindra R Shah; Paramjeet Singh Kapoor; Praveen Taneja; Akhilesh Sharma; Chandrashekhar Bolmall; Vidyagauri P Baliga
Journal:  Curr Ther Res Clin Exp       Date:  2009-02

5.  A randomized, double-blind, placebo-controlled study of daily cannabidiol for the treatment of canine osteoarthritis pain.

Authors:  Chris D Verrico; Shonda Wesson; Vanaja Konduri; Colby J Hofferek; Jonathan Vazquez-Perez; Emek Blair; Kenneth Dunner; Pedram Salimpour; William K Decker; Matthew M Halpert
Journal:  Pain       Date:  2020-09-01       Impact factor: 7.926

6.  Salidroside Alleviates Cartilage Degeneration Through NF-κB Pathway in Osteoarthritis Rats.

Authors:  Hui Gao; Lu Peng; Chao Li; Qinlong Ji; Ping Li
Journal:  Drug Des Devel Ther       Date:  2020-04-14       Impact factor: 4.162

7.  Robenacoxib shows efficacy for the treatment of chronic degenerative joint disease-associated pain in cats: a randomized and blinded pilot clinical trial.

Authors:  Derek Adrian; Jonathan N King; Rudolph S Parrish; Stephen B King; Steven C Budsberg; Margaret E Gruen; B Duncan X Lascelles
Journal:  Sci Rep       Date:  2021-04-08       Impact factor: 4.379

8.  Chronic Pain Management During a Pandemic: Evidence-Based Review.

Authors:  Niyati Arora; Ajit Kumar; Ajay Kumar; Ravi Shankar Sharma
Journal:  Turk J Anaesthesiol Reanim       Date:  2022-06

9.  Evaluation of the effect of D-002, a mixture of beeswax alcohols, on osteoarthritis symptoms.

Authors:  Roberto Puente; José Illnait; Rosa Mas; Daisy Carbajal; Sarahí Mendoza; Julio César Fernández; Meilis Mesa; Rafael Gámez; Pablo Reyes
Journal:  Korean J Intern Med       Date:  2014-02-27       Impact factor: 2.884

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.